Editorial
Welcome to the first homepage edition of i2P for 2012.
In many ways it has been a slow start to the New Year because of having to deal with the “leftovers” from 2011.
One of those items for i2P was that a third-party provider to the site did not advise of a code change to the security section in our subscribe panel, creating a range of frustrated subscribers not able to get on board.
We apologise to all those potential subscribers who were unable to register with us in the second half of 2011, but if you try once more you should have no problem.
Columns
Rollo Manning: Pharma-Goss
Linda Bryant: Inside NZ
Loretta Marron BSc: Health Watch
Barry Urquhart: Marketing Focus
Mark Neuenschwander: I`ve been thinking about...Recent Comments
Past Editions
Volume 1 Number 1
Volume 1 Number 2
Volume 1 Number 3
Volume 1 Number 4
Volume 1 Number 5
Volume 1 Number 6
Volume 1 Number 7
Volume 2 Number 1
Volume 2 Number 2
Volume 2 Number 3
Volume 2 Number 4
Volume 2 Number 5
Volume 2 Number 6
Volume 2 Number 7
Volume 2 Number 8
Volume 2 Number 9
Volume 2 Number 10
Volume 2 Number 11
Volume 3 Number 1
Volume 3 Number 2
Volume 3 Number 3
Volume 3 Number 4
Volume 3 Number 5
Volume 3 Number 6
Volume 3 Number 7
Volume 3 Number 8
Volume 3 Number 9
Volume 3 Number 10
Volume 3 Number 11
Volume 2012 Number 1
Health Politics
Neil Johnston: Friends of Science in Medicine
Peter Sayers: Confessions of a Frustrated Pharmacist
James Ellerson: $75.5 million in 5CPA lying idle. Why is it so?EPublications
Inflammation in Fat Cells Causes Insulin Resistance
Printer-friendly version
Send to friend
PDF version | Staff Writer |
Editing and Researching news and stories about global and local Pharmacy Issues | |
Inflammation-causing cells in fat tissue may explain the link between obesity and diabetes, a team of Walter and Eliza Hall Institute researchers has shown.
The discovery, by Professor Len Harrison and Dr John Wentworth from the institute’s Autoimmunity and Transplantation division, opens the way for new anti-inflammatory treatments that prevent insulin resistance (where the body is unable to respond to and use the insulin it produces) and other complications associated with obesity.
“We have shown that insulin resistance in human obesity is closely related to the presence of inflammatory cells in fat tissue, in particular a population of macrophage cells,” Professor Harrison said.
Macrophages, white blood cells derived from the bone marrow, are immune cells that normally respond to infections. In obese people, macrophages move into the fat tissue where they cause inflammation and release cytokines, which are chemical messenger molecules used by immune cells to communicate. Certain cytokines cause cells to become resistant to the effects of the hormone insulin, leading to diabetes and heart disease.
Professor Harrison and Dr Wentworth worked with Mr Gaetano Naselli, Ms Belinda Phipson and Dr Gordon Smyth at the institute as well as Professor Paul O’Brien at Monash University’s Centre for Obesity Research and Education to analyse the fat tissue of more than 100 Victorians who had undergone lapband surgery.
Their findings, published in the journal Diabetes, provide the first evidence in humans that macrophages in the fat tissue are producing cytokines that prevent cells from appropriately responding to the presence of insulin.
“The complications of obesity such as insulin resistance and diabetes, cardiovascular disease associated with hardening of the arteries, and liver problems are the result of inflammation that occurs in the fat tissue,” Professor Harrison said. “These complications could be prevented by developing drugs that target certain cytokines released by the macrophages.
“Encouragingly, our study also showed that when obese people lost weight the macrophages in the fat tissue disappeared, as did the risk of developing insulin resistance and diabetes.”
Diabetes affects more than a million Australians and is a disease in which the body does not produce or properly use insulin, a hormone necessary to convert sugar, starches and other food into the energy needed for daily life.
The research was supported by the Australian National Health and Medical Research Council, the Victorian Government, Diabetes Australia Research Trust and the Royal Australasian College of Physicians Research and Education Foundation.
Return to homeResearch Reports
Dr Andrew Byrne & Associates: Tranquillizer use rife amongst OTP subjects world-wide, most legally prescribedPractice Development
Neil Retallick: Are the discounters impacting community pharmacy beyond margin erosion? | open full screen
Kay Dunkley - BPharm, Grad Dip Hosp Pharm, Grad Dip Health Admin, MPS, MSHPA: Support services for pharmacists and doctors in the United Kingdom – Part 3 Royal Medical Benevolent Fund | open full screen
Staff Writer: Catch the early wave in 2012 and secure your valuable CPD Credits at the Guild Pharmacy Academy – NSW Convention | open full screen
Information Technology
Dr David More: Australian Health Information Technology LinksIndigenous Health
Preventive Medicine
Gerald Quigley: It’s Time!If any difficulty is found in subscribing, please use the "Contact Us" panel found in the navigation bar with the message "subscribe" and your email address.
Post new comment